Ipsen announces new data to be presented at ASCO in line with its continued commitment to Oncology research


Ipsen today announced that lanreotide (Somatuline® Autogel® Depot), cabozantinib (Cabometyx®), irinotecan liposome injection (Onivyde®) and the investigational compounds 177Lu-OPS201 and 68Ga-OPS201 are the subject of presentations at the American Society of Clinical Oncology (ASCO) 2017 conference. The meeting takes place in Chicago, Illinois, June 2-6, 2017.

“Ipsen continues to build on the strength of its Oncology portfolio at ASCO this year with new data being presented to support our key products as well as our early-stage radiopharmaceutical compounds,”, said David Meek, Chief Executive Officer, Ipsen. “We are establishing a leadership position in several specialty Oncology markets and will continue to collaborate with the research community to accelerate the discovery and development of therapeutic options with the goal of improving the lives of people living with cancer.”

“These studies demonstrate Ipsen’s steadfast commitment to cancer patients for whom innovative options are urgently needed,” said Alexandre Lebeaut, MD, Executive Vice-President, R&D, Chief Scientific Officer, Ipsen. “Researchers are sharing deeper insights from Ipsen’s oncology’s portfolio to continue to improve treatment of gastroenteropancreatic neuroendocrine tumors, advanced pancreatic cancer and advanced renal cell carcinoma.”


© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2022